These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 7970188)
1. Supersensitivity of quinpirole-evoked GTPase activation without changes in gene expression of D2 and Gi protein in the striatum of hemi-dopaminergic lesioned rats. Inoue A; Ueda H; Nakata Y; Misu Y Neurosci Lett; 1994 Jul; 175(1-2):107-10. PubMed ID: 7970188 [TBL] [Abstract][Full Text] [Related]
2. Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats. Ueda H; Sato K; Okumura F; Inoue A; Nakata Y; Ozaki N; Yue JL; Misu Y Biomed Pharmacother; 1995; 49(4):169-77. PubMed ID: 7669936 [TBL] [Abstract][Full Text] [Related]
3. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. LaHoste GJ; Marshall JF Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762 [TBL] [Abstract][Full Text] [Related]
4. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity. LaHoste GJ; Yu J; Marshall JF Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797 [TBL] [Abstract][Full Text] [Related]
5. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
6. Perinatal Treatments with the Dopamine D₂-Receptor Agonist Quinpirole Produces Permanent D₂-Receptor Supersensitization: a Model of Schizophrenia. Kostrzewa RM; Nowak P; Brus R; Brown RW Neurochem Res; 2016 Feb; 41(1-2):183-92. PubMed ID: 26547196 [TBL] [Abstract][Full Text] [Related]
7. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767 [TBL] [Abstract][Full Text] [Related]
8. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies. Hu XT; White FJ Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772 [TBL] [Abstract][Full Text] [Related]
9. Dopaminergic and muscarinic regulation of striatal enkephalin and substance P messenger RNAs following striatal dopamine denervation: effects of systemic and central administration of quinpirole and scopolamine. Nisenbaum LK; Kitai ST; Gerfen CR Neuroscience; 1994 Nov; 63(2):435-49. PubMed ID: 7534387 [TBL] [Abstract][Full Text] [Related]
11. Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa. Asin KE; Bednarz L; Nikkel A; Perner R J Pharmacol Exp Ther; 1995 Jun; 273(3):1483-90. PubMed ID: 7791123 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding. Engber TM; Marin C; Susel Z; Chase TN Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970 [TBL] [Abstract][Full Text] [Related]
13. Ontogenic homologous supersensitization of quinpirole-induced yawning in rats. Kostrzewa RM; Brus R Pharmacol Biochem Behav; 1991 Jun; 39(2):517-9. PubMed ID: 1682952 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological and biochemical characterization of dopamine receptors mediating stimulation of a high affinity GTPase in rat striatum. Onali P; Olianas MC Biochem Pharmacol; 1987 Sep; 36(17):2839-45. PubMed ID: 2820423 [TBL] [Abstract][Full Text] [Related]
15. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum. Zhou LW; Zhang SP; Qin ZH; Weiss B J Pharmacol Exp Ther; 1994 Feb; 268(2):1015-23. PubMed ID: 8113958 [TBL] [Abstract][Full Text] [Related]
16. Dorsal striatal mechanisms involved in the dopamine D2 receptor-mediated potentiation of apomorphine-induced jaw movements. Kikuchi de Beltrán K; Koshikawa N; Miwa Y; Kobayashi M Eur J Pharmacol; 1994 Jan; 252(1):99-104. PubMed ID: 7908646 [TBL] [Abstract][Full Text] [Related]
17. Dopaminergic grafts in the striatum reduce D1 but not D2 receptor-mediated rotation in 6-OHDA-lesioned rats. Robertson GS; Fine A; Robertson HA Brain Res; 1991 Jan; 539(2):304-11. PubMed ID: 1675908 [TBL] [Abstract][Full Text] [Related]
19. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems. Singh NA; Bush LG; Gibb JW; Hanson GR Brain Res; 1992 Feb; 571(2):260-4. PubMed ID: 1351780 [TBL] [Abstract][Full Text] [Related]
20. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Engber TM; Boldry RC; Kuo S; Chase TN Brain Res; 1992 May; 581(2):261-8. PubMed ID: 1356580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]